伊朗总统佩泽希齐扬：如果没有巴基斯坦的努力，我们今天就不会取得这样的成就。

【期货热点追踪】美国天气炒作攻略：美豆、美玉米优良率符合市场预期，但美国中西部地区天气或影响大豆作物生长？

Sinovac Biotech’s fully human anti-tetanus monoclonal antibody SNA02-48 injection has entered a Phase III trial, with the first volunteer enrolled at Shenzhen Second People’s Hospital. SNA02-48 was cleared for clinical use in March 2025 and is a recombinant fully human mAb for emergency post-exposure prophylaxis against tetanus. Sinovac is expanding a wound-care portfolio covering active and passive immunity: its adsorbed tetanus vaccine is market-approved; Sinovac-backed Xingmeng Biotech’s Class 1 innovative drug Krebi® (monoclonal antibody injection) is approved for passive immunization of adults exposed to rabies; Sinovac’s lyophilized human rabies vaccine (serum-free Vero cell) is in the regulatory filing stage.